Search clinical trials for: V512

Total 32 results

Merck Sharp & Dohme LLC

Completed

A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults

Influenza
Huazhong University of Science and Technology

Recruiting

Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions

Human Papillomavirus-Related Malignant Neoplasm

China
Merck Sharp & Dohme LLC

Withdrawn

A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)

Herpes Zoster
Merck Sharp & Dohme LLC

Withdrawn

Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

Cervical Cancer | Condylomata Acuminata
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Herpes Zoster | Herpes Zoster-related Complications
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

Herpes Zoster
Vernalis (R&D) Ltd
Syneos Health; Cita NeuroPharmaceuticals

Completed

PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

Parkinson's Disease

Italy
Nantes University Hospital

Terminated

Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia (rTMS)

Hemiplegia

France
Atrium Medical Corporation

Completed

Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta

Coarctation of the Aorta

Israel, Australia, Brazil, Canada, Germany, Italy, United Kingdom
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Herpes Zoster
Coordinación de Investigación en Salud, Mexico
Instituto Mexicano del Seguro Social

Terminated

Total Parenteral Nutrition Associated Cholestasis (TPNAC) and Plasma Amino Acid Levels in Neonates (TPNAC)

Premature Birth

Mexico
Bial - Portela C S.A.

Completed

Effect of Food on BIA 6-512 (Trans-resveratrol)

Parkinson Disease

Portugal
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Genital Warts | Human Papilloma Virus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Herpes Zoster
Erasmus Medical Center

Active, not recruiting

Covered Stents Versus Bare-Metal Stents

Necrosis | Arteriosclerosis | Stenosis | Lifestyle-related Condition | Gastrointestinal Vascular Conditions | Vascular Insufficiency

Netherlands
InfaCare Pharmaceuticals Corporation, a Mallinckrodt...

Terminated

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

Hyperbilirubinemia, Neonatal

United States, Spain, Poland, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)

Herpes Zoster
Samyang Biopharmaceuticals Corporation
Chungnam National University Hospital

Completed

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Healthy, Male
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Medtronic Diabetes

Completed

Obtain a Good Blood Glucose Control With the Paradigm Real Time System (RTD)

Type 1 Diabetes

France
Medtronic Diabetes

Completed

In Clinic Evaluation of the PLGM Feature (PLGM)

Type 1 Diabetes

United States
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
Darnitsa Pharmaceutical Company
ACDIMA Biocenter

Completed

Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers

Healthy Subjects | Bioequivalence

Jordan
Bial - Portela C S.A.

Completed

Tolerability and Steady-state Pharmacokinetics of BIA 6-512

Parkinson Disease

Portugal
Woolsey Pharmaceuticals

Active, not recruiting

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) (REAL)

Amyotrophic Lateral Sclerosis

United States, Australia
University Hospital, Tours

Completed

PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)

Cirrhotic Portal Hypertension

France
Xijing Hospital
First Affiliated Hospital Xi'an Jiaotong University; Shanghai 10th People's... and other collaborators

Terminated

Preoperative Vitamin B12 and Folic Acid on POCD in Elderly Non-cardiac Surgical Patients (B12-POCD)

Post Operative Cognitive Dysfunction

China
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

Parkinson Disease

Portugal

3

Subscribe